Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Provided By Globe Newswire

Last update: Jan 26, 2022

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted recent operational and corporate updates. The Company also announced that it has changed its name to Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”).